ArticleTranslational lung cancer research2025
Natural course of lung adenocarcinoma manifesting as ground-glass nodules: invasiveness assessment based on growth evaluation.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Investigating the growth characteristics of lung adenocarcinoma manifesting as ground-glass nodules (gLUAD) and assessing its invasiveness based on these features are crucial for optimizing follow-up and intervention strategies. This study aimed to systematically analyze the growth dynamics of gLUAD and compare the value of different growth evaluation methods in predicting gLUAD invasiveness. Methods: A total of 564 participants with 625 gLUAD were retrospectively enrolled from the First and Fourth Medical Centers of the Chinese PLA General Hospital between January 2018 and December 2022. gLUAD was pathologically classified into two categories: adenocarcinoma in situ (AIS)/minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IAC). Growth evaluation was conducted using four definitions (size growth, volume growth, mass growth, and stage shift) and two growth models (linear and exponential models). These methods were further evaluated in terms of their effectiveness in assessing gLUAD invasiveness. Results: The median follow-up period of gLUAD in this study was 1,050 days. The median doubling times for total/solid size, volume, and mass of gLUAD were >3,650/3,042 days, 1,460/1,014 days, and 1,521/1,014 days, respectively. For AIS/MIA, all doubling times exceeded 3,650 days, whereas for IAC, they were 3,318/2,147 days, 1,141/777 days, and 1,074/760 days, respectively. The R Conclusions: gLUAD exhibited an indolent growth pattern, with significant differences in growth trends between AIS/MIA and IAC. Both the linear and exponential growth models showed similar fitting performance for gLUAD growth, while the linear growth model provided a more reliable assessment of invasiveness. The LGR of total mass offered superior differentiation between AIS/MIA and IAC and may serve as a valuable auxiliary indicator for assessing gLUAD invasiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.